ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > MD&A

<< Previous

Bullboard Posts

Next >>

Comment by M101on May 18, 2022 11:33pm

244 Views

Post# 34694437

RE:RE:RE:RE:RE:RE:RE:RE:MD&A

goldtech wrote: Gene and Elliott had no plans to take this private ...

Yes, exactly, they had no plans because they couldn't do it without losing control. They kept it public instead and tried to keep control through ever-worse band-aid financings instead of courting major investors, until facing bankruptcy they had no choice.
So for those who missed the Hemmingway reference (since it got no likes): An old fisherman in small boat catches the fish of his life, it takes him far out to sea and when he finally reels it in it is too big to pull into the boat. He ties it to the side and starts to row home, but by landfall the sharks have left him with nothing.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta